Close X
Attorney Spotlight

After finishing her first year as an associate at Bass, Berry & Sims, find out what advice Margaret Dodson offers to new attorneys. Read more>


Close X


Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Blueprint for an IPO

Companies go public to raise capital to fuel growth, pay down debt and provide liquidity to shareholders. Although all issuers and offerings are different, the basic process of going public remains relatively constant. Blueprint for an IPO identifies the key players, details the process and identifies the obligations companies will face after going public.

Read now

Steele Clayton Interviews FTC Bureau of Competition Director Richard Feinstein

Media Mentions

January 8, 2010

Steele Clayton, attorney at Bass, Berry & Sims and assistant leader of the firm's Antitrust & Trade Practices Group, along with Toby Singer of Jones Day in Washington, D.C., has conducted an interview with Federal Trade Commission Bureau of Competition Director Richard Feinstein for the American Health Lawyers Association Practice Group Member Briefing.

The interview is described as follows:

The Obama Administration is still just beginning to put its stamp on the federal antitrust enforcement agencies. But new appointees at the Federal Trade Commission (FTC) have signaled that they will continue the FTC's strong emphasis on antitrust enforcement in the healthcare arena. FTC Director of the Bureau of Competition Richard Feinstein has particular expertise in healthcare antitrust, having served as assistant director for the Health Care Services and Products Division of the Bureau of Competition in the Clinton Administration, and having continued to practice healthcare antitrust law in private practice after his government service. The AHLA Antitrust Practice Group posed a set of questions to Mr. Feinstein to elicit his views on healthcare antitrust enforcement policy for the FTC now and in the future. Access the Member Briefing entitled, "Questions for Richard Feinstein, Director of the Bureau of Competition at the Federal Trade Commission," which contains the transcript of the interview.

There are a number of responses of particular interest. Mr. Feinstein characterizes one of the FTC's top priorities as "aggressive" merger enforcement. He explains what we can expect to see in future hospital merger challenges, both procedurally and substantively. He warns against adopting the view that concentration in insurer markets justifies further concentration in provider markets, and states that the FTC examines physician group mergers in the same way that it examines other types of mergers. With respect to clinical integration, Mr. Feinstein reveals that there is more guidance on the way and that the FTC will be having more discussions with groups interested in clinical integration. Other issues addressed are FTC Act Section 5 enforcement, efforts to amend the antitrust laws, and more.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.